Regeneron Reports First Quarter 2017 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 hits record high as rate-hike worries ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Burry doubles down on Nebius short after stock surges 34% on earnings
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Home Depot CEO Ted Decker takes medical leave; two executives step in
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Regeneron Pharma (REGN) PT Raised to $475 at Cowen
May 4, 2017 3:39 PM EDTCowen raised its price target on Regeneron Pharma (NASDAQ: REGN) to $475.00 (from $380.00) while maintaining a Market Perform rating following Q1 results.
Analyst Phil Nadeau is updating estimates to reflect Dupixent's fast start, Eylea's deceleration.
FY 2017 EPS goes from $12.25 to $1.25 and FY 2018 EPS goes from $14.90 to $13.20.
... MoreRegeneron (REGN) Misses Q1 EPS by 15c, Offers FY Guidance
May 4, 2017 6:40 AM EDTRegeneron (NASDAQ: REGN) reported Q1 EPS of $2.92, $0.15 worse than the analyst estimate of $3.07. Revenue for the quarter came in at $1.32 billion versus the consensus estimate of $1.3... More
